![Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles | Translational Medicine Communications | Full Text Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles | Translational Medicine Communications | Full Text](https://media.springernature.com/lw685/springer-static/image/art%3A10.1186%2Fs41231-019-0050-7/MediaObjects/41231_2019_50_Fig1_HTML.png)
Lost in translation: the valley of death across preclinical and clinical divide – identification of problems and overcoming obstacles | Translational Medicine Communications | Full Text
![PHASE II STUDY DESIGNS: PART 2 Resident and Fellows Lecture Series April 12, 2016 Elizabeth Garrett-Mayer, PhD Hollings Cancer Center. - ppt download PHASE II STUDY DESIGNS: PART 2 Resident and Fellows Lecture Series April 12, 2016 Elizabeth Garrett-Mayer, PhD Hollings Cancer Center. - ppt download](https://images.slideplayer.com/36/10622641/slides/slide_3.jpg)
PHASE II STUDY DESIGNS: PART 2 Resident and Fellows Lecture Series April 12, 2016 Elizabeth Garrett-Mayer, PhD Hollings Cancer Center. - ppt download
![Understanding Clinical Trial Terminology: What's a Phase 1, 2 or 3 Clinical Trial? - Concert Pharmaceuticals Understanding Clinical Trial Terminology: What's a Phase 1, 2 or 3 Clinical Trial? - Concert Pharmaceuticals](https://www.concertpharma.com/wp-content/uploads/2019/09/9-3-19-Persepectives-blog-What-is-Phase-1-2-3-image-for-9-3-19-final-.jpg)
Understanding Clinical Trial Terminology: What's a Phase 1, 2 or 3 Clinical Trial? - Concert Pharmaceuticals
![Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial - The Lancet Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial - The Lancet](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/8b72eb65-35f0-4367-abe2-49882d563804/gr1_lrg.gif)
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial - The Lancet
![Agile research to complement agile development: a proposal for an mHealth research lifecycle | npj Digital Medicine Agile research to complement agile development: a proposal for an mHealth research lifecycle | npj Digital Medicine](https://media.springernature.com/m685/springer-static/image/art%3A10.1038%2Fs41746-018-0053-1/MediaObjects/41746_2018_53_Fig1_HTML.png)